With regard to the government’s procurement of vaccines during the COVID-19 pandemic: (a) what price did Canada negotiate per vaccine from each manufacturer, and what was the final price paid per vaccine for each manufacturer; (b) what were the amounts, in Canadian dollars, broken down by vaccine product and company, of advance payments made by the government to pharmaceutical companies to guarantee vaccine shipments; (c) what confidentiality and indemnification clauses did Canada agree to in order to exempt companies from legal liability; (d) were pharmaceutical companies exempted from the obligation to give full refunds if deliveries were delayed or cancelled; (e) what clauses, if any, did the vaccine purchase contracts signed by Canada include relating to the ability of Canada to donate vaccine doses from those contracts to low- and middle-income countries, humanitarian organizations, Gavi, the World Health Organization, or any other organization for use outside of Canada;
(f) when Canada’s Chief Public Health Officer indicated, in October 2021, that initial agreements between Canada and the manufacturers of mRNA vaccines (e.g. Moderna and Pfizer/BioNTech) did not allow for doses to be donated but that new arrangements had been made to permit donations, what were the original conditions and the subsequently agreed conditions, respectively; (g) what is the total value, in Canadian dollars, of funding provided by the government, broken down by department or agency, to support the research, development, or manufacture of vaccines, drugs, or diagnostic tests for COVID-19 between 2020 and 2023; (h) for any of the funding provided during this time to companies, universities, not-for-profits, or other research, development, or manufacturing entities, did any of the funding agreements or contracts contain clauses or stipulations that would secure a pricing structure for the final product for Canadians or for people living in low- and middle-income countries; (i) did Canada attempt to use its leverage as an investor in these technologies to secure fair or affordable pricing of the final products for Canadians or for people living in low and middle income countries; and (j) did Canada attempt to use its leverage as an investor in these technologies to ensure access to the final products for Canadians or for people living in low and middle income countries, for example by requiring the products to be registered for use in Canada or in low and middle income countries?